

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Secukinumab for treating moderate to severe plaque psoriasis

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final Appraisal Determination

(when no ACD was issued)

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

No equalities issues were identified in the scoping process.
--

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
|--|

A patient organisation commented that people with psoriatic arthritis affecting their fingers could find using the pre-filled syringe difficult, as could those with a needle phobia. The Committee concluded that the monthly administration of secukinumab would be easier to manage for these patients than of other biological agents that need to be injected more. Bearing in mind that the Committee had recommended secukinumab, it concluded that there was no need to alter or add to its recommendations. It also noted that a separate appraisal was being considered for secukinumab for people with psoriatic arthritis.
--

- | |
|--|
| 3. Have any other potential equality issues been identified by the |
|--|

Committee, and, if so, how has the Committee addressed these?

No additional issues were identified by the Committee.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A

7. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

FAD section 4.22.

Approved by Programme Director (name): Meindert Boysen

Date: 13/05/2015

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of Secukinumab for treating moderate to severe plaque psoriasis

Issue date: July 2015